• English
  • 简体中文
Login Register
Current Location: Home > Feedback Help Print

【结 构 式】

【药物名称】SB-204070

【化学名称】8-Amino-7-chloro-1,4-benzodioxan-5-carboxylic acid 1-butylpiperidin-4-ylmethyl ester

【CA登记号】148702-58-3

【 分 子 式 】C19H27ClN2O4

【 分 子 量 】382.89104

【开发单位】GlaxoSmithKline (Originator)

【药理作用】GASTROINTESTINAL DRUGS, Irritable Bowel Syndrome, Agents for, 5-HT4 Antagonists

合成路线1

The chlorination of 8-acetamido-2,3-dihydro-1,4-benzodioxin-5-carboxylic acid (I) with chlorine in acetic acid gives the 7-chloro derivative (II), which is treated with aqueous NaOH to yield 8-amino-2,3-dihydro-1,4-benzodioxin-5-carboxylic acid (III). The reaction of (III) with carbonyldiimidazole (CDI) affords the activated intermediate (IV), which is finally condensed with 1-(1-butylpiperidin-4-yl)methanol (V) by means of MeLi in THF. The intermediate 1-(1-butylpiperidin-4-yl)methanol (V) has been obtained by condensation of piperidine-4-carboxylic acid ethyl ester (VI) with 1-bromobutane (VII) by means of K2CO3 in methanol, followed by reduction of the ester group with LiAlH4 in THF.

1 Bulteau, G.; Acher, J.; Thominet, M.; Collignon, C. (Ile de France); Substituted 2,3-alkylenedioxybenzamides. DE 2734270; FR 2360305; GB 1571278; GB 1571447; JP 53018570; US 4186135; US 4248885; US 4255580 .
2 Gaster, L.M.; Sanger, G.J.; SB-204070: 5-HT4 receptor antagonists and their potential therapeutic utility. Drugs Fut 1994, 19, 12, 1109.
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(I) 41270 8-(acetamido)-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid C11H11NO5 详情 详情
(II) 41271 8-(acetamido)-7-chloro-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid C11H10ClNO5 详情 详情
(III) 41272 8-amino-7-chloro-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid C9H8ClNO4 详情 详情
(IV) 41273 (8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)(1H-imidazol-1-yl)methanone C12H10ClN3O3 详情 详情
(V) 41274 (1-butyl-4-piperidinyl)methanol C10H21NO 详情 详情
(VI) 17410 Ethyl isonipecotate; ethyl 4-piperidinecarboxylate 1126-09-6 C8H15NO2 详情 详情
(VII) 28721 1-bromobutane 109-65-9 C4H9Br 详情 详情
Extended Information